Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

被引：15
|
作者：
Kater, Arnon P. [1 ]
Christensen, Jacob Haaber [2 ]
Bentzen, Hans Herluf [3 ]
Niemann, Carsten Utoft [4 ]
Hutchings, Martin [4 ]
Chen, Jenny [5 ]
Rios, Marcia [6 ]
Palenski, Tammy [6 ]
Li, Tommy [5 ]
Mato, Anthony R. [7 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands
[2] Odense Univ Hosp, Odense, Denmark
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Copenhagen Univ Hosp, Rigshospitalet, Copenhagen, Denmark
[5] Genmab, Princeton, NJ USA
[6] AbbVie, N Chicago, IL USA
[7] Mem Sloan Kettering Canc Ctr, Chron Lymphocyt Leukemia Program, New York, NY USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146563
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2627
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [22] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [23] Subcutaneous Epcoritamab Versus Standard of Care in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase 3 EPCORE DLBCL-1 Trial
    Fox, Christopher P.
    Roost, Clausen Michael
    Pieternella, Lugtenburg
    Balari, Anna S.
    Zinzani, Pier L.
    Jun, Wu
    Laura, Finn
    Vindelov, Signe D.
    Catherine, Thieblemont
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S32 - S33
  • [24] Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Bose, Prithviraj
    Fowler, Nathan H.
    Kadia, Tapan M.
    Daver, Naval G.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
  • [25] A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barr, Paul M.
    Hill, Brian T.
    Ma, Shuo
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Zent, Clive S.
    BLOOD, 2019, 134
  • [26] Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial
    Amrein, Philip C.
    Attar, Eyal
    Takvorian, Tak
    Hochberg, Ephraim
    Ballen, Karen K.
    Leahy, Kathleen M.
    Neuberg, Donna
    Brown, Jennifer R.
    BLOOD, 2008, 112 (11) : 1084 - 1084
  • [27] Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results
    Linton, Kim M.
    Wahlin, Bjorn
    Leppa, Sirpa
    Morschhauser, Franck
    Elliott, Brian
    Liu, Tracy
    Stirner, Mariana Cota
    Abbas, Aqeel
    Falchi, Lorenzo
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 94 - 94
  • [28] Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)
    Cairo, Mitchell S.
    Rocco, Mark A.
    Bernard, John
    Siddani, Satya R.
    Parikh, Apurvasena
    Elliott, Brian
    Burkhardt, Birgit
    BLOOD, 2022, 140 : 3827 - 3828
  • [29] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
    Mazza, Irit Avivi
    Kim, Won Seog
    Ko, Shen
    Grande, Carlos
    Lavie, David
    Chism, David
    Seliem, Mostafa
    Jeng, Edwin E.
    Joshi, Neha
    Siddani, Satya
    Assaily, Wissam
    Sacchi, Mariana
    Dinh, Minh
    Avigdor, Abraham
    BLOOD, 2023, 142
  • [30] Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Zhou, Keshu
    Xing, Hongyun
    Teng, Qingliang
    Li, Wuping
    Wang, Yafei
    Zhu, Feng
    Jin, Zhengming
    Zhiming, Li
    Ouyang, Guifang
    Xu, Fang
    Huang, Shihua
    Li, Jianyong
    BLOOD, 2024, 144 : 4628 - 4628
12345